leadf
logo-loader
viewEmerald Clinics Ltd

Emerald Clinics partners with New York’s Mt Sinai Hospital for Openly platform

The company has partnered with Mt Sinai Hospital’s Precision Recovery team to support ongoing development of Emerald’s Openly clinical service for the remote monitoring of patients and care coordination.

Emerald Clinics Ltd - Emerald Clinics partners with New York’s Mt Sinai Hospital for Openly platform
The Openly platform has recently been registered as a Class 1 medical device with the TGA

Emerald Clinics Ltd (ASX:EMD) has entered a professional services agreement with the Precision Recovery team at New York’s Mt Sinai Hospital, one of the USA's leading teaching and research hospitals, to support ongoing development of Emerald’s Openly clinical service.

The Precision Recovery Team is currently managing over 1,600 COVID-positive, COVID-suspected and COVID-recovering individuals remotely and has special expertise in this area.

Under the agreement, Mt Sinai’s Precision Recovery team will provide remote monitoring and consulting services to support the development and delivery of Emerald’s Openly clinical service worldwide, in exchange for access to the Openly app and a payment for any alert reviewed by the Mt Sinai team on request.

“Improving wellness screening services”

Emerald CEO Dr Michael Winlo said the agreement with Mt Sinai would improve the health and wellness screening services that could be delivered on the Openly platform to support workforces get back to business.

He said: “This agreement allows Emerald to benefit from the real-world experiences and expertise of the Precision Recovery team which will help enhance the capabilities of the Openly technology as well as the health screening services our clinical team can deliver.

“We’re thrilled to be working with such an innovative and world-leading organisation to advance remote patient care.”

COVID clinical challenges

Mount Sinai Precision Recovery Team director Assistant Professor David Putrino said the COVID-19 pandemic had presented a considerable challenge to healthcare providers providing remote clinical services.

He said: “COVID-19 has fundamentally changed the way that we provide high-quality medical care and thrust the use of technology in healthcare to the forefront.

“Where possible, management of mild to moderate COVID cases should happen in the home, and we have been working to develop innovative technologies and clinician workflows that enable healthcare professionals to keep sick patients safe at home.”

Openly platform

Openly is a digital health and wellness screening service provided via smart mobile devices and backed by Emerald’s clinical team.

Alerts may be generated by the Openly platform when certain survey responses or other health information is entered by the user.

The criteria for generating alerts are configured uniquely for each client and updated by Emerald’s clinical experts as more data is acquired by the system.

Alert review requests made to the Precision Recovery team will be initiated at the discretion of Emerald’s clinical team.

The platform has recently been registered as a Class 1 medical device with the Australian Therapeutic Goods Administration (TGA).

Quick facts: Emerald Clinics Ltd

Price: 0.083 AUD

ASX:EMD
Market: ASX
Market Cap: $17.55 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Emerald Clinics Ltd named herein, including the promotion by the Company of Emerald Clinics Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Emerald Clinics makes first big move into UK with Spectrum Biomedical deal

Emerald Clinics Ltd (ASX:EMD) CEO Dr Michael Winlo talks to Proactive about his company’s new partnership with Spectrum Biomedical UK to develop a real-world evidence data system in the UK. Shares in the company soared in response to the agreement which will see Emerald design and deliver...

on 11/8/20

2 min read